OakChart

Krystal Biotech Inc

KRYSHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 8:08 AM ET

306.00-0.50 (-0.16%)
2026-11-11 15:29 CET
Market cap
9,082.67 USD m
Revenue, TTM
470.02 USD m
Net income, TTM
225.17 USD m
Free cash flow, TTM
310.08 USD m
EPS diluted, TTM
7.36
P/E
41.55
Compare

Price

KRYS against its 20, 50 and 200-day averages
2050200beat
250.00300.00350.002.3M4.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KRYSclose 306.0020-day 314.3550-day 329.31200-day 309.40306.00

20.0% under 382.54 on 30 Jun 2026. Last 15 sessions, 18.2% high to low

Profile

KRYS
52-week range, 59% of the way up
198.02382.54

Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

IndexRUT
Employees295
IPOSep 20, 2017
Beta0.66
ATR, 14d11.46
Rel volume0.00
Short float11.71%
Insider own12.26%
Inst own98.70%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap9.07B
Enterprise Value8.16B
Income225.17M
Sales470.02M
Book/sh48.45
Cash/sh30.77
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees295
IPOSep 20, 2017

Ratios

P/E41.55
Forward P/E33.03
PEG1.68
P/S19.29
P/B6.32
P/C9.94
P/FCF29.24
EV/EBITDA34.85
EV/Sales17.37
Quick Ratio7.53
Current Ratio7.89
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)7.36
EPS next Y9.27
EPS next Q2.04
EPS this Y12.18%
EPS next Y20.75%
EPS next 5Y19.62%
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM11.21%
Sales Y/Y TTM25.96%
EPS Q/Q-23.13%
Sales Q/Q30.21%
EarningsNov 02 BMO
EPS/Sales Surpr.14.59% 1.25%

Ownership

Insider Own12.26%
Insider Trans-3.37%
Inst Own98.70%
Inst Trans-0.74%
ROA15.93%
ROE17.50%
ROIC15.61%
Gross Margin93.02%
Oper. Margin48.41%
Profit Margin47.91%
SMA20-2.66%
SMA50-7.08%
SMA200-1.10%
Trades-

Technical

Shs Outstand29.63M
Shs Float26.00M
Short Float11.71%
Short Ratio10.87
Short Interest3.04M
52W High382.54 -20.01%
52W Low198.02 54.53%
Volatility3.70% 3.71%
ATR (14)11.46
RSI (14)43.20
Beta0.66
Rel Volume0.00
Avg Volume280.14K
Volume42

Performance

Perf Week-1.56%
Perf Month-4.72%
Perf Quarter-6.80%
Perf Half Y-2.11%
Perf YTD24.12%
Perf Year50.74%
Perf 3Y210.47%
Perf 5Y519.68%
Perf 10Y-
Recom1.25
Target Price401.25
Prev Close306.50
Price306.00
Change %-0.16%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 24, 2026ResumedGGoldmanBuy$441+44.1%
Aug 14, 2026InitiatedRRBC Capital MktsOutperform$400+30.7%
Mar 27, 2026InitiatedWWolfe ResearchPeer Perform
Jan 06, 2026UpgradeCCitigroupNeutral → Buy$309+1.0%
Mar 05, 2025InitiatedJJefferiesBuy$245-19.9%
Aug 06, 2024DowngradeCCitigroupBuy → Neutral$195 → $204-33.3%
Nov 20, 2023InitiatedGGoldmanBuy$160-47.7%
Oct 24, 2023InitiatedCCantor FitzgeraldOverweight$100-67.3%
Oct 12, 2023InitiatedCCitigroupBuy$160-47.7%
Sep 07, 2023InitiatedBBerenbergBuy$154-49.7%

Peers

Mkt cap
TickerCompanyMkt cap
ABEOAbeona Therapeutics Inc140.01M
BMRNBiomarin Pharmaceutical Inc11.09B
SRPTSarepta Therapeutics Inc1.78B
PTCTPTC Therapeutics Inc5.26B
RAREUltragenyx Pharmaceutical Inc1.65B
VCELVericel Corp3.01B
RGNXRegenxbio Inc497.90M
RYTMRhythm Pharmaceuticals Inc7.89B
ARQTArcutis Biotherapeutics Inc3.52B
RCKTRocket Pharmaceuticals Inc268.95M

Insider trading

latest 14 of 49
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Krishnan SumaPresident, R&DSep 04 '26Sale359.3225,0008,982,9861,302,145Sep 04 07:15 PM
Krishnan Krish SPresident and CEOSep 04 '26Sale359.3225,0008,983,0841,347,543Sep 04 07:14 PM
SUMA KRISHNANDirectorSep 04 '26Proposed Sale371.4725,0009,286,750Sep 04 04:34 PM
KRISH KRISHNANDirectorSep 04 '26Proposed Sale371.4725,0009,286,750Sep 04 04:34 PM
ROSSI DINO ADirectorAug 14 '26Sale329.1225,0008,227,95350,000Aug 14 06:22 PM
Dino A. RossiDirectorAug 14 '26Proposed Sale332.2725,0008,306,750Aug 14 05:21 PM
Thomas John CharlesEVP, General CounselJun 25 '26Option Exercise179.251,000179,2501,000Jun 26 06:45 PM
Thomas John CharlesEVP, General CounselJun 25 '26Sale347.271,000347,2700Jun 26 06:45 PM
Thomas John CharlesOfficerJun 25 '26Proposed Sale347.271,000347,270Jun 25 10:03 AM
Krishnan SumaPresident, R&DJun 04 '26Sale308.1125,0007,702,8251,378,155Jun 05 06:40 PM
Krishnan Krish SPresident and CEOJun 04 '26Sale308.1225,0007,702,9841,450,253Jun 05 06:38 PM
SUMA KRISHNANDirectorJun 04 '26Proposed Sale301.8225,0007,545,500Jun 04 04:30 PM
KRISH KRISHNANDirectorJun 04 '26Proposed Sale301.8225,0007,545,500Jun 04 04:30 PM
Thomas John CharlesEVP, General CounselMay 26 '26Sale302.03642193,9030May 27 05:17 PM

Held by

AUM
TickerCompanyAUM
IJHiShares Core S&P Mid-Cap ETFAUM: 124.48B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XMMOInvesco S&P MidCap Momentum ETFAUM: 6.37B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
DFASU.S. Small Cap Portfolio-ETF Class Shares-

News

latest 14 of 206
  • Krystal Biotech to Present at Upcoming Investor Conferences (GlobeNewswire)
  • Krystal Biotech Beats On Vyjuvek Strength And Adds A $400 Million Buyback, But Pipeline Timelines Slip Into 2027 (Earnings Whispers) -10.95%
  • Krystal Biotech Shares Fall 3.7% Despite Q3 Earnings Beat and 30% Revenue Growth (InvestorsHub)
  • Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results (GlobeNewswire)
  • Krystal Biotech's Germany Pricing Drag Tests Whether Vyjuvek Demand Can Carry Q3 (Earnings Whispers)
  • Loading…
  • Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026 (GlobeNewswire)
  • Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions Begin (InvestorsHub)
  • Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome (GlobeNewswire)
  • Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial (FinanceWire)
  • Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference (GlobeNewswire)
  • Earnings Calendar and Analysis for This Week (August 10-14) (Kiplinger)
  • J&J pharma leader to retire; Krystal slumps on gene therapy miss (BioPharma Dive)
  • Krystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: VYJUVEK Sales Surge 24% as ... (GuruFocus.com) -8.37%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-022.0501.7892.050127.34125.7710
2026Q22026-08-031.7901.7011.787119.22120.9310
2026Q12026-05-041.8301.4901.833116.36112.1110
2025Q42026-02-171.7001.5441.699107.11105.359
2025Q32025-11-032.6601.0902.66097.8093.199
2025Q22025-08-041.2901.1851.28996.0491.9710
2025Q12025-05-061.2001.4271.19688.1896.219
2024Q42025-02-191.5201.1841.52291.1490.648
2024Q32024-11-040.9100.9940.90983.8482.9410
2024Q22024-08-050.5300.7330.52570.2865.279
2024Q12024-05-060.0300.2660.03245.2547.379
2023Q42024-02-260.300-0.3080.30242.1428.5510
2023Q32023-11-062.790-1.2012.7958.566.296
2023Q22023-08-07-1.250-1.265-1.2460.000.006
2023Q12023-05-08-1.760-1.439-1.7620.000.147
2022Q42023-02-27-1.250-1.259-1.2480.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.200-1.223-1.2000.000.00
2020FY-1.710-1.792-1.7120.000.00
2021FY-3.130-2.844-3.1340.000.00
2022FY-5.490-5.406-5.4910.000.00
2023FY0.390-0.1200.39450.7036.32
2024FY3.0002.7572.998290.52289.95
2025FY6.8406.7506.960389.13387.65
2026FY-7.673--497.5
2027FY-9.265--646.3
2028FY-11.708--844.03
2029FY-22.605--1,422
2030FY-31.398--1,925

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-041024134.02129.66137.24
2026Q4S2026-11-021024134.52129.66138
2026Q4S2026-10-281006135.13125.23148.8
2026Q4S2026-10-201106133.86121.1148.8
2026Q4S2026-10-171105134.65121.1148.8
2026Q4S2026-10-151108134.65121.1148.8
2026Q4S2026-10-141108135.71121.1148.8
2026Q4S2026-10-131108135.71121.1148.8
2026Q4S2026-10-121117136.92121.1153.9
2026Q4S2026-10-091117137.61121.1153.9
2026Q4S2026-10-071117137.92121.1153.9
2026Q4S2026-10-031116142.12121.1195
2026Q4S2026-09-291117142.12121.1195
2026Q4S2026-09-231116142.38121.1195

Estimate history

EPS, annual-1.48-0.972-1.2-1.712-3.134-5.4910.3942.9986.8397.3642
Period201720182019202020212022202320242025TTM
EPS, quarterly0.9091.5221.1961.2892.661.6991.8331.7872.045
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000050.699290.515389.13470.02
Period201720182019202020212022202320242025TTM
Sales, quarterly83.84191.13988.18396.04297.8107.105116.357119.222127.341
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual10.30714.42917.35419.71425.20825.76428.23728.79429.19229.631
Period201720182019202020212022202320242025MRQ
Shares, quarterly28.75728.79428.89928.92728.98429.19229.43729.59629.631
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue470.02389.13290.5150.700.000.000.000.000.00
Cost of Goods Sold Incl. D&A32.8228.7726.818.104.052.771.850.970.14
Gross Profit437.21360.36263.7142.60-4.05-2.77-1.85-0.97-0.14
Selling, General and Administrative Excl. Other209.69199.06160.51139.82116.1465.5131.1521.1111.78
Research and Development53.6252.3253.5746.4339.8626.0817.9415.627.76
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income227.52161.29103.19-97.23-120.20-68.28-33.00-22.08-11.92
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.0037.5012.5025.000.000.00--
Net Income Before Taxes258.80189.4795.3612.90-139.97-69.57-32.17-19.09-10.89
Income Taxes33.63-15.366.201.970.000.000.000.000.00
Consolidated Net Income225.17204.8389.1610.93-139.97-69.57-32.17-19.09-10.89
Net Income From Continuing Operations225.17204.8389.1610.93-139.97-69.57-32.17-19.09-10.89
Net Income225.17204.8389.1610.93-139.97-69.57-32.17-19.09-10.89
EPS (Recurring)7.306.843.880.71-4.80-3.13-1.71-1.20-0.97
EPS (Basic, Before Extraordinaries)7.667.083.120.40-5.49-3.13-1.71-1.20-0.97
EPS (Diluted)7.366.843.000.39-5.49-3.13-1.71-1.20-0.97
EBITDA234.26167.85109.94-92.22-116.14-65.51-31.15-21.11-11.78
Non-Operating Income (Expense)31.2828.1829.66122.625.22-1.290.832.991.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense43.8243.0736.8526.8031.4513.673.271.240.79
Price To Earnings Ratio41.6241.6288.62------
Price To Sales Ratio21.8218.9816.0467.91-----
Gross Margin93.0292.6190.7784.02-----
Operating Margin48.4141.4535.52-191.77-----
Net Margin47.9152.6430.6921.56-----
Shares Outstanding29.6329.1928.7928.2425.7625.2119.7117.3514.43
Market Capitalization9,082.679,082.674,505.623,499.272,039.721,742.191,182.46958.52299.83

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue127.34119.22116.36107.1197.8096.0488.1891.14
Cost of Goods Sold Incl. D&A9.037.797.848.155.668.716.666.54
Gross Profit118.31111.43108.5198.9592.1487.3381.5284.60
Selling, General and Administrative Excl. Other47.1753.0154.8254.6850.7648.0345.3443.22
Research and Development13.4213.1613.8113.2313.1914.4114.2613.52
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income71.1458.4253.6944.2741.3739.3136.1841.38
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes80.1466.0861.4451.1347.9746.7743.6048.61
Income Taxes17.0811.315.51-0.27-31.408.447.863.13
Consolidated Net Income63.0754.7755.9351.4079.3638.3335.7345.48
Net Income From Continuing Operations63.0754.7755.9351.4079.3638.3335.7345.48
Net Income63.0754.7755.9351.4079.3638.3335.7345.48
EPS (Recurring)2.051.791.831.702.661.291.201.52
EPS (Basic, Before Extraordinaries)2.131.851.911.772.741.331.241.58
EPS (Diluted)2.051.791.831.702.661.291.201.52
EBITDA72.8359.9855.4146.0342.9840.8537.8142.97
Non-Operating Income (Expense)9.007.667.756.866.597.477.427.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.0111.1810.7510.8710.3911.1510.6510.02
Price To Earnings Ratio41.6249.6837.7436.9835.9133.1060.3488.62
Price To Sales Ratio21.8225.8718.8819.1714.1111.3816.1516.11
Gross Margin92.9193.4693.2692.3994.2190.9392.4592.83
Operating Margin55.8749.0046.1441.3342.3040.9341.0245.40
Net Margin49.5345.9448.0747.9981.1539.9140.5249.90
Shares Outstanding29.6329.6029.4429.1928.9828.9328.9028.79
Market Capitalization9,082.6710,956.767,551.267,149.045,109.313,972.425,193.744,505.62

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments827.79597.52532.18379.17438.10271.26193.69111.7649.59
Short Term Receivables127.42104.7542.040.000.000.000.000.000.00
Inventories40.4826.516.990.000.000.000.000.000.00
Other Current Assets28.9113.276.714.614.173.802.190.890.32
Total Current Assets1,024.60742.04587.91383.78442.27275.06195.88112.6549.91
Net Property, Plant & Equipment158.01161.45168.23169.73119.5834.1711.183.010.20
Total Investments and Advances128.07152.1161.954.6264.370.000.500.000.00
Intangible Assets--------0.00
Deferred Tax Assets22.82--------
Other Assets0.290.230.260.320.071.611.460.450.00
Total Assets1,333.791,055.84818.36558.45626.29310.84209.02116.1250.11
Short Term Debt Incl. Current Port. of LT Debt1.771.221.471.561.048.240.480.000.00
Accounts Payable3.244.994.133.988.402.100.720.890.19
Other Current Liabilities97.9395.7927.4923.3016.305.112.121.710.45
Total Current Liabilities102.94102.0033.0928.8525.7415.453.332.600.64
Long Term Debt7.576.046.627.376.983.312.780.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities3.721.420.000.000.000.000.000.290.00
Total Liabilities114.23109.4639.7136.2232.7218.766.112.890.64
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,219.56946.38778.64522.23593.58292.08202.91113.2349.47
Total Shareholders Equity1,219.56946.38778.64522.23593.58292.08202.91113.2349.47
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,219.56946.38778.64522.23593.58292.08202.91113.2349.47
Total Liabilities & Stockholders Equity1,333.791,055.84818.36558.45626.29310.84209.02116.1250.11
Book Value Per Share41.7832.8727.5820.2723.5514.8211.697.854.80
Tangible Book Value Per Share41.7832.8727.5820.2723.5514.8211.697.854.80
Full-Time Employees29527522921011975513712
Price to Book Ratio6.335.094.633.772.974.054.742.652.15
Return on Assets17.149.511.59-23.63-14.85-12.38-11.74-13.10-30.29
Return on Equity18.9110.341.68-25.09-15.71-13.00-12.08-13.39-31.83
Return on Invested Capital16.699.361.39-26.43-11.58-10.89-9.28-9.62-16.01
Quick Ratio9.567.0217.5513.3017.1817.8058.8843.3977.99
Current Ratio9.957.2817.7613.3017.1817.8058.8843.3977.99

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income225.17204.8389.1610.93-139.97-69.57-32.17-19.09-10.89
Depreciation6.746.556.715.014.052.771.850.970.14
Other Funds (Non Cash)52.7848.7542.00-66.8632.5416.813.311.310.79
Funds from Operations284.43237.28137.88-50.92-103.38-49.99-27.01-16.81-9.96
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital39.50-36.42-14.46-37.882.812.050.93-1.910.51
Cash from Operating Activities323.93200.87123.42-88.80-100.57-47.94-26.08-18.71-9.45
Capital Expenditures-13.85-11.95-4.24-11.80-52.98-68.34-14.84-6.40-2.23
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.430.000.000.000.000.000.00-
Purchase or Sale of Investments-258.14-46.90-159.20-5.56-61.10-158.433.661.43-8.09
Purchase of Investments-684.55-422.54-457.74-508.78-318.78-190.46-3.21-9.07-8.09
Sale Or Maturity of Investments426.42375.64298.54503.21257.6832.036.8710.500.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.00100.000.000.000.000.000.00
Cash from Investing Activities-271.99-58.42-163.4482.64-114.08-226.77-11.18-4.97-10.32
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock40.7722.6632.40203.5036.00355.64118.02107.5373.85
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock40.7722.6632.40203.5036.00355.64118.02107.5373.85
Proceedsfrom Stock Options0.000.0032.40203.5036.00355.64118.02107.5373.85
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-17.10-13.96-5.39-0.75-0.650.000.000.000.00
Other Financing Activities Uses-17.10-13.96-5.39-0.75-0.650.000.000.000.00
Cash from Financing Activities23.678.7127.01202.7535.35347.69118.02107.5373.85
Exchange Rate Effect-5.380.29-0.46-0.16-0.04----
Net Change in Cash70.24151.44-13.46196.43-179.3572.9880.7583.8454.08
Free Cash Flow310.08188.91119.18-100.60-153.55-116.27-40.93-25.11-11.68
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow33.0739.0939.09------
Deferred Taxes & Investment Tax Credit--22.840.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments911.85845.63823.40827.79731.07681.99
Short Term Receivables133.12138.66127.02127.42129.63111.44
Inventories50.7945.5642.6540.4837.6331.04
Other Current Assets26.0129.8026.6728.9127.3216.88
Total Current Assets1,121.761,059.651,019.741,024.60925.65841.35
Net Property, Plant & Equipment158.90160.60160.62158.01156.32158.04
Total Investments and Advances282.30257.29193.49128.07133.11138.81
Deferred Tax Assets22.8222.8222.8222.8224.68-
Other Assets0.270.280.300.290.330.20
Total Assets1,586.061,500.651,396.971,333.791,240.091,138.39
Short Term Debt Incl. Current Port. of LT Debt1.821.811.801.771.701.62
Accounts Payable6.736.544.093.242.107.12
Income Tax Payable----9.54-
Other Current Liabilities133.60119.05101.9197.9377.9378.16
Total Current Liabilities142.14127.40107.80102.9491.2786.90
Long Term Debt6.777.047.317.577.818.06
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.567.085.123.723.142.79
Total Liabilities150.47141.52120.24114.23102.2297.75
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,435.581,359.131,276.731,219.561,137.881,040.65
Total Shareholders Equity1,435.581,359.131,276.731,219.561,137.881,040.65
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,435.581,359.131,276.731,219.561,137.881,040.65
Total Liabilities & Stockholders Equity1,586.061,500.651,396.971,333.791,240.091,138.39
Book Value Per Share48.4545.9243.3741.7839.2635.97
Tangible Book Value Per Share48.4545.9243.3741.7839.2635.97
Full-Time Employees---295--
Price to Book Ratio6.338.576.186.284.914.03
Return on Assets15.9318.3018.2117.1417.9014.27
Return on Equity17.5020.1219.9018.9119.6615.61
Return on Invested Capital4.374.014.364.196.933.66
Quick Ratio7.537.969.069.569.739.33
Current Ratio7.898.329.469.9510.149.68

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income63.0754.7755.9351.4079.3638.33
Depreciation1.691.571.731.761.611.54
Other Funds (Non Cash)12.9713.5813.2213.0111.2412.36
Funds from Operations76.9669.1770.3068.0167.5452.23
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital14.295.6210.089.50-27.880.49
Cash from Operating Activities91.2574.7980.3877.5139.6652.73
Capital Expenditures-1.00-3.56-7.15-2.14-1.70-1.90
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-56.99-158.02-56.4413.30-2.58-8.62
Purchase of Investments-194.04-258.02-160.03-72.46-98.37-113.90
Sale Or Maturity of Investments137.05100.00103.6085.7695.79105.28
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-57.98-161.58-63.5811.16-4.29-10.53
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.4215.166.5015.693.711.80
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.4215.166.5015.693.711.80
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.01-0.11-16.96-0.02-0.010.00
Other Financing Activities Uses-0.01-0.11-16.96-0.02-0.010.00
Cash from Financing Activities3.4115.05-10.4615.673.711.80
Exchange Rate Effect-1.58-1.83-1.33-0.64-0.311.06
Net Change in Cash35.10-73.575.01103.7038.7745.06
Free Cash Flow90.2571.2273.2375.3737.9550.83
Price to Free Cash Flow33.0744.2033.2039.4831.8022.05

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 290.52M 2025: 389.13M
United States2024: 290.52M 2025: 389.13M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.71%3.0M26.0M275.58K
2026-10-1511.31%2.9M26.0M368.86K
2026-09-3013.38%3.5M26.0M373.41K
2026-09-1512.18%3.2M26.0M403.06K
2026-08-3112.89%3.3M26.0M409.11K
2026-08-1412.37%3.2M25.9M409.92K
2026-07-3112.37%3.2M25.9M424.82K
2026-07-1513.56%3.5M25.8M321.55K
2026-06-3013.64%3.5M25.8M313.32K
2026-06-1512.18%3.1M25.8M285.78K
2026-05-2912.24%3.1M25.7M277.90K
2026-05-1512.38%3.2M25.7M305.41K
2026-04-3012.08%3.1M25.6M279.45K
2026-04-1511.42%2.9M25.5M287.48K
2026-03-3112.38%3.1M25.3M303.65K
2026-03-1311.40%2.9M25.3M292.45K
2026-02-2711.64%2.9M25.3M307.42K
2026-02-1310.90%2.8M25.3M285.49K
2026-01-3010.89%2.7M24.9M314.60K
2026-01-1510.66%2.7M24.9M308.57K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1300.000.00172.56-1.000.00---
call1350.000.000.00-0.000.00---
call1400.000.000.00-0.000.00---
call1450.000.000.00-0.000.00---
call1500.000.00155.5-1.000.00---
call1550.000.000.00-0.000.00---
call1600.000.000.00-0.000.00---
call1650.000.000.00-0.000.00---
call1700.000.00163.8-2.000.00---
call1750.000.0096.40-1.000.00---
call1800.000.00149-5.000.00---
call1850.000.000.00-0.000.00---
call1900.000.000.00-0.000.00---
call1950.000.000.00-0.000.00---
call2000.000.00123-8.000.00---
call2100.000.0092.70-1.000.00---
call2200.000.00145-0.000.00---
call2300.000.0086.00-6.000.00---
call2400.000.00100.6-4.000.00---
call2500.000.0038.00-21.000.00---
call2600.000.0030.00-18.000.00---
call2700.000.0087.56-9.000.00---
call2800.000.0033.05-52.000.00---
call2900.000.0013.50-16.000.00---
call3000.000.0010.30-2710.00---
call3100.000.007.35-45.000.00---
call3200.000.003.00-1950.00---
call3300.000.003.17-72.000.00---
call3400.000.002.15-6790.00---
call3500.000.000.60-1280.00---
call3600.000.003.60-52.000.00---
call3700.000.000.67-1580.00---
call3800.000.002.55-37.000.00---
call3900.000.001.90-41.000.00---
call4000.000.000.06-21.000.00---
call4100.000.0011.70-14.000.00---
call4200.000.001.96-13.000.00---
call4300.000.001.80-23.000.00---
call4400.000.007.80-20.000.00---
call4500.000.006.17-12.000.00---
call4600.000.005.80-9.000.00---
call4700.000.0016.20-1.000.00---
call4800.000.000.00-0.000.00---
call4900.000.000.00-0.000.00---
call5000.000.000.00-0.000.00---
call5200.000.003.79-1.000.00---
call5400.000.003.41-1.000.00---
call5600.000.000.98-2.000.00---
put1300.000.000.20-20.000.00---
put1350.000.000.55-9.000.00---
put1400.000.000.00-0.000.00---
put1450.000.000.00-0.000.00---
put1500.000.000.00-0.000.00---
put1550.000.000.00-0.000.00---
put1600.000.000.00-0.000.00---
put1650.000.000.00-0.000.00---
put1700.000.000.00-0.000.00---
put1750.000.004.22-23.000.00---
put1800.000.000.00-0.000.00---
put1850.000.003.27-1.000.00---
put1900.000.001.06-1.000.00---
put1950.000.000.00-0.000.00---
put2000.000.000.59-5.000.00---
put2100.000.001.69-1.000.00---
put2200.000.001.91-3.000.00---
put2300.000.000.35-17.000.00---
put2400.000.000.80-22.000.00---
put2500.000.001.00-13.000.00---
put2600.000.001.92-9.000.00---
put2700.000.001.00-23.000.00---
put2800.000.003.00-14.000.00---
put2900.000.003.50-17.000.00---
put3000.000.006.50-35.000.00---
put3100.000.0015.20-20.000.00---
put3200.000.0018.84-34.000.00---
put3300.000.0035.00-1840.00---
put3400.000.0052.50-39.000.00---
put3500.000.0031.60-4.000.00---
put3600.000.0032.30-7.000.00---
put3700.000.000.00-0.000.00---
put3800.000.000.00-0.000.00---
put3900.000.00123.8-0.000.00---
put4000.000.000.00-0.000.00---
put4100.000.000.00-0.000.00---
put4200.000.000.00-0.000.00---
put4300.000.00110.9-0.000.00---
put4400.000.0088.79-0.000.00---
put4500.000.000.00-0.000.00---
put4600.000.00158.13-0.000.00---
put4700.000.00168.1-16.000.00---
put4800.000.00121.4-0.000.00---
put4900.000.00131-0.000.00---
put5000.000.000.00-0.000.00---
put5200.000.000.00-0.000.00---
put5400.000.00191-0.000.00---
put5600.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-028-KCurrent report2026-11-02SEC
2026-11-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-158-KCurrent report2026-10-15SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-08-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-218-KCurrent report2026-07-21SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-25144Filing for proposed sale of securities under Rule 144.SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-04144Filing for proposed sale of securities under Rule 144.SEC
2026-06-04144Filing for proposed sale of securities under Rule 144.SEC
2026-05-274Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-26144Filing for proposed sale of securities under Rule 144.SEC
2026-05-208-KCurrent report2026-05-15SEC
2026-05-048-KCurrent report2026-05-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090017.97M2
2026-08008.23M1
2026-070000
2026-060015.75M3
2026-0500193.90K1
2026-040000
2026-030013.36M3
2026-020027.76M7
2026-010000
2025-120022.01M4
2025-110000

Institutional holders

Manager% owned
FMR LLC15.00%
BlackRock, Inc.14.18%
Avoro Capital Advisors LLC9.80%
VANGUARD PORTFOLIO MANAGEMENT LLC5.34%
STATE STREET CORP4.58%
VANGUARD CAPITAL MANAGEMENT LLC4.21%
Soleus Capital Management, L.P.3.19%
GEODE CAPITAL MANAGEMENT, LLC2.74%
Capital World Investors2.64%
VESTOR CAPITAL, LLC2.38%

Funds

Fund% owned
Select Biotechnology Portfolio6.09%
iShares Core S&P Small-Cap ETF5.36%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
Fidelity Growth Company Fund2.76%
SMALLCAP World Fund Inc2.55%
iShares Russell 2000 ETF2.28%
VANGUARD SMALL-CAP INDEX FUND2.18%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.26%
Hood River Small-Cap Growth Fund1.12%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.08%

OakChart. KRYS. Cached 15 minutes.